Seroatlas · Human Serome Atlas

MED17

Mediator of RNA polymerase II transcription subunit 17

Also known as: CRSP6, CRSP77, DRIP80, MED17_HUMAN, SRB4, TRAP80

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9NVC6
Gene: MED17
Ensembl: ENSG00000042429
Chromosome: 11
Canonical length: 651 aa
Protein class: Cancer-related genes, Disease related genes, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins
Subcellular location: Nuclear speckles,Cytosol

OverviewNCBI Gene

The activation of gene transcription is a multistep process that is triggered by factors that recognize transcriptional enhancer sites in DNA. These factors work with co-activators to direct transcriptional initiation by the RNA polymerase II apparatus. The protein encoded by this gene is a subunit of the CRSP (cofactor required for SP1 activation) complex, which, along with TFIID, is required for efficient activation by SP1. This protein is also a component of other multisubunit complexes e.g. thyroid hormone receptor-(TR-) associated proteins which interact with TR and facilitate TR function on DNA templates in conjunction with initiation factors and cofactors. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

651 residues, UniProt reviewed canonical sequence.

>Q9NVC6|MED17
     1  MSGVRAVRIS IESACEKQVH EVGLDGTETY LPPLSMSQNL ARLAQRIDFS QGSGSEEEEA
    61  AGTEGDAQEW PGAGSSADQD DEEGVVKFQP SLWPWDSVRN NLRSALTEMC VLYDVLSIVR
   121  DKKFMTLDPV SQDALPPKQN PQTLQLISKK KSLAGAAQIL LKGAERLTKS VTENQENKLQ
   181  RDFNSELLRL RQHWKLRKVG DKILGDLSYR SAGSLFPHHG TFEVIKNTDL DLDKKIPEDY
   241  CPLDVQIPSD LEGSAYIKVS IQKQAPDIGD LGTVNLFKRP LPKSKPGSPH WQTKLEAAQN
   301  VLLCKEIFAQ LSREAVQIKS QVPHIVVKNQ IISQPFPSLQ LSISLCHSSN DKKSQKFATE
   361  KQCPEDHLYV LEHNLHLLIR EFHKQTLSSI MMPHPASAPF GHKRMRLSGP QAFDKNEINS
   421  LQSSEGLLEK IIKQAKHIFL RSRAAATIDS LASRIEDPQI QAHWSNINDV YESSVKVLIT
   481  SQGYEQICKS IQLQLNIGVE QIRVVHRDGR VITLSYQEQE LQDFLLSQMS QHQVHAVQQL
   541  AKVMGWQVLS FSNHVGLGPI ESIGNASAIT VASPSGDYAI SVRNGPESGS KIMVQFPRNQ
   601  CKDLPKSDVL QDNKWSHLRG PFKEVQWNKM EGRNFVYKME LLMSALSPCL L

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against MED17 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.39
Highest tissue expression: 2.1 nTPM

Expression across tissuesHPA

Tissue

spleen: 2.1 nTPM
small intestine: 2 nTPM
endometrium: 1.7 nTPM
ovary: 1.7 nTPM
bone marrow: 1.6 nTPM
cerebellum: 1.6 nTPM

Single-cell type

choroid plexus epithelial cells: 39 nCPM
microglia: 34 nCPM
oligodendrocyte progenitor cells: 33 nCPM
brain excitatory neurons: 32 nCPM
oligodendrocytes: 32 nCPM
brain inhibitory neurons: 30 nCPM

Immune cell

memory B-cell: 8.3 nTPM
eosinophil: 7.6 nTPM
NK-cell: 6.9 nTPM
naive B-cell: 5.8 nTPM
T-reg: 5.3 nTPM
naive CD4 T-cell: 5.2 nTPM

Brain region

cerebellum: 10 nTPM
cerebral cortex: 8.9 nTPM
white matter: 8.7 nTPM
choroid plexus: 7.9 nTPM
medulla oblongata: 6.3 nTPM
thalamus: 6.1 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about MED17.

Disease | AllUniProt

Conditions MED17 is implicated in, by any mechanism.

Microcephaly, postnatal progressive, with seizures and brain atrophy (MCPHSBA) MIM:613668

Disease | GeneticClinVar

84 pathogenic / likely-pathogenic of 721 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.78
gnomAD pLI: 0
gnomAD missense Z: 0.88
DepMap mean gene effect: -1.08
DepMap dependency class: common

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

Mediator complex, subunit Med17
Subunit 17 of Mediator complex

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of MED17 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads MED17 as an antibody target. Whether an autoantibody or antibody against MED17 could matter depends on whether native MED17 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

MED17 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label MED17 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...